the future of Herceptin with nanotechnology
 

These experiments in the below study, have shown that Nanoparticles covalently coupled with antibodies, like herceptin bind to cancer cells in both a pretargeting and a direct approach. In theroy, nanoparticles coupled with Herceptin may be a useful drug carrier for tumor targeting. These nanoparticles could either hold radioactive substances to help diagnose metastatic cancer or chemotherapeutic agents to target and kill her2 metastatic cells.


Published 18 January 2006 in Bioconjug Chem, 17(1): 139-145.
Full-text of this article is available online (may require subscription).